MOREPEN LABS share price has plunged 3% and is presently trading at Rs 58.7.
Meanwhile, the BSE HEALTHCARE index is at 41,010.6 (up 0.4%).
Among the top losers in the BSE HEALTHCARE index today are GRANULES INDIA (down 2.2%) and DR. LAL PATHLABS (down 2.1%).
ALEMBIC PHARMA (up 3.1%) and ERIS LIFESCIENCES (up 2.6%) are among the top gainers today.
Over the last one year, MOREPEN LABS has moved up from Rs 33.1 to Rs 58.7, registering a gain of Rs 25.6 (up 77.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 41,010.6, registering a gain of 44.9% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 117.0%), GSK Pharma (up 105.8%) and SUVEN PHARMACEUTICALS (up 104.6%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,281.5 (down 0.2%).
The top losers among the BSE Sensex today are Infosys (down 1.6%) and JSW Steel (down 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,221.7 (down 0.3%). JSW Steel and Infosys are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 79,281.5, registering a gain of 13,328.0 points (up 20.2%).
MOREPEN LABS net profit grew 248.7% YoY to Rs 287 million for the quarter ended March 2024, compared to a profit of Rs 82 million a year ago. Net sales rose 16.3% to Rs 4,231 million during the period as against Rs 3,637 million in January-March 2023.
For the year ended March 2023, MOREPEN LABS reported 62.0% decrease in net profit to Rs 387 million compared to net profit of Rs 1,017 million during FY22. Revenue of the company fell 8.4% to Rs 14,175 million during FY23.
The current Price to earnings ratio of MOREPEN LABS, based on rolling 12 month earnings, stands at 33.3.
Equitymaster requests your view! Post a comment on "MOREPEN LABS Plunges 3%; BSE HEALTHCARE Index Up 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!